VACCIBODY REGISTRATION AND TRADING ON NOTC

Vaccibody AS will be registered on the NOTC-list as of January 27, 2020 under the ticker "VACC"

Oslo, January 26, 2020 -- Vaccibody AS, a leading biopharmaceutical company dedicated to developing novel cancer vaccine therapies, announces that it will register on the Norwegian OTC-list ("NOTC"), owned and operated by Oslo Børs, from and including January 27, 2020.

Vaccibody will trade under the ticker "VACC". The company has pt. issued 55,797,676 shares each with a par value NOK 0.05, all of which are VPS registered with ISIN code NO0010714785. The company has entered into an agreement whereby it will use the NOTC reporting systems as of January 27, 2020.

Chair of the Board Anders Tuv comments: "Vaccibody has received considerable interest from investors, particularly since the very promising and positive first read-outs from the VB10.NEO personalized cancer vaccine trial. The registration on the NOTC-list will facilitate trading and price transparency in the company's shares".

About Vaccibody
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is now enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma of head and neck. Vaccibody has a collaboration with Nektar Therapeutics, planning to start testing VB10.NEO in combination with bempegaldesleukin (NKTR-214) in squamous cell carcinoma of head and neck. Vaccibody's front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), evaluating the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) has been finalized and has reported positive 12 months data. Vaccibody has started a collaboration with Roche, which will explore VB10.16 in combination with PD-L1 inhibitor atezolizumab (Tecentriq®) in up to 50 patients with advanced or recurrent cervical cancer. First patient in this study is expected to be vaccinated in Q1 2020. Further information about the company and its drug development programs and capabilities may be found online at http://www.vaccibody.com

For more information, please contact:
Anders Tuv, Chairman
Tel: +47 982 06 826
E-mail: ATuv@Vaccibody.com